ERIC 2022 | Resistance mechanisms in CLL and the importance of genomic re-testing
Barbara Eichhorst
• 7 Oct 2022
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, discusses resistance mechanisms in chronic lymphocytic leukemia (CLL), highlighting the importance of genomic testing in this disease. Dr Eichhorst explains that TP53 testing should always be performed at relapse in order to select patients for allogeneic hematopoietic stem cell transplantation (alloHSCT) or to include these patients in clinical trials evaluating CAR-Ts or bispecific antibodies. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
